Tessa E. Hendriks

Tessa E. Hendriks

Auto-generated profile, based on publicly available information

Tessa E. Hendriks

Department of Surgery, Amsterdam UMC, location University of Amsterdam, Amsterdam, the Netherlands

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2013 in International Journal of Colorectal Disease
Verified
Journal Article
Closed access
PDF file
RVR. J. van der Vijver
R. J. van der Vijver
CLC. J. H. M. van Laarhoven
C. J. H. M. van Laarhoven
RLR. M. L. M. Lomme
R. M. L. M. Lomme
THT. Hendriks
T. Hendriks

3 May 2024 in British Journal of Surgery
Verified
Journal Article
Open access
PDF file
MGMichelle R de Graaff
Michelle R de Graaff
THTessa E Hendriks
Tessa E Hendriks
MWMichel Wouters
Michel Wouters
MNMark Nielen
Mark Nielen
IHIgnace de Hingh
Ignace de Hingh
NKNiels F M Kok
Niels F M Kok
Background: Clinical auditing is a powerful tool to evaluate and improve healthcare. Deviations from the expected quality of care are identified by benchmarking the results of individual hospitals using national averages. This study aimed to evaluate the use of quality indicators for benchmarking hepato-pancreato-biliary (HPB) surgery and when outlier hospitals could be identified. Methods: A population-based study used data from two nationwide Dutch HPB audits (DHBA and DPCA) from 2014 to 2021. Sample size calculations determined the threshold (in percentage points) to identify centres as statistical outliers, based on current volume requirements (annual minimum of 20 resections) on a two-year period (2020–2021), covering mortality rate, failure to rescue (FTR), major morbidity rate and textbook/ideal outcome (TO) for minor liver resection (LR), major LR, pancreaticoduodenectomy (PD) and distal pancreatectomy (DP). Results: In total, 10 963 and 7365 patients who underwent liver and pancreatic resection respectively were included. Benchmark and corresponding range of mortality rates were 0.6% (0 −3.2%) and 3.3% (0–16.7%) for minor and major LR, and 2.7% (0–7.0%) and 0.6% (0–4.2%) for PD and DP respectively. FTR rates were 5.4% (0–33.3%), 14.2% (0–100%), 7.5% (1.6%–28.5%) and 3.1% (0–14.9%). For major morbidity rate, corresponding rates were 9.8% (0–20.5%), 28.1% (0–47.1%), 36% (15.8%–58.3%) and 22.3% (5.2%–46.1%). For TO, corresponding rates were 73.6% (61.3%–94.4%), 54.1% (35.3–100), 46.8% (25.3%–59.4%) and 63.3% (30.7%–84.6%). Mortality rate thresholds indicating a significant outlier were 8.6% and 15.4% for minor and major LR and 14.2% and 8.6% for PD and DP. For FTR, these thresholds were 17.9%, 31.6%, 22.9% and 15.0%. For major morbidity rate, these thresholds were 26.1%, 49.7%, 57.9% and 52.9% respectively. For TO, lower thresholds were 52.5%, 32.5%, 25.8% and 41.4% respectively. Higher hospital volumes decrease thresholds to detect outliers. Conclusion: Current event rates and minimum volume requirements per hospital are too low to detect any meaningful between hospital differences in mortality rate and FTR. Major morbidity rate and TO are better candidates to use for benchmarking.

6 November 2025 in British Journal of Surgery
Verified
Journal Article
Open access
AEAnouk M L H Emmen
Anouk M L H Emmen
BBBram L J van Den Broek
Bram L J van Den Broek
THTessa E Hendriks
Tessa E Hendriks
OBOlivier Busch
Olivier Busch
BBBert A Bonsing
Bert A Bonsing
MGMembers of the Dutch Institute for Clinical Auditing and the Dutch Pancreatic Cancer Group
Members of the Dutch Institute for Clinical Auditing and the Dutch Pancreatic Cancer Group
Background: Robotic pancreatoduodenectomy (RPD) is increasingly being implemented to enhance patient recovery, but it is unclear what happens to patient outcomes after the initial learning curve. The aim of this study was to evaluate the first 1000 consecutive RPD performed in the Netherlands. Methods: A nationwide analysis of patients who underwent RPD in 13 centres (March 2016–August 2023) from the Dutch Pancreatic Cancer Audit was performed. Patients were grouped based on published learning curve cut-offs (phases 1–4): 1–15, 16–62, 63–84, and >84 RPD per centre respectively. Outcomes were compared between the four learning curve phases. Ideal Outcome rates were used to compare outcomes between centres. Results: Overall, 1000 patients after RPD were included. The conversion rate was 10.1%, the rate of Clavien–Dindo complications of grade ≥III was 41.3%, the rate of postoperative pancreatic fistula of grade B/C was 24.4%, and the rate of in-hospital/30-day mortality was 3.9%. Of the patients, 71.1% had a high updated alternative fistula risk score. Improvements between the phases were found for five outcomes: median operating time (420, 360, 349, and 369 min respectively; P < 0.001), conversion rate (21.7%, 10.0%, 2.8%, and 7.5% respectively; P < 0.001), rate of delayed gastric emptying (DGE) of grade B/C (32.3%, 22.6%, 15.4%, and 20.2% respectively; P = 0.003), reoperation rate (9.9%, 11.3%, 9.8%, and 4.9% respectively; P = 0.026), and median duration of hospital stay (12, 11, 10, and 10 days respectively; P = 0.035). The rate of Clavien–Dindo complications of grade ≥III and the rate of in-hospital/30-day mortality remained stable. The Ideal Outcome rate (mean 47%) did not differ between centres. Conclusion: Across four learning curve phases in a nationwide cohort, improvements were observed for operating time, conversion rate, rate of DGE of grade B/C, reoperation rate, and duration of hospital stay.

7 January 2025 in HPB
Verified
Journal Article
Open access
JCJeffrey W. Chen
Jeffrey W. Chen
SASimone Augustinus
Simone Augustinus
BBBert A. Bonsing
Bert A. Bonsing
SBStefan A.W. Bouwense
Stefan A.W. Bouwense
IHIgnace H.J.T. De Hingh
Ignace H.J.T. De Hingh
EDEls Nieveen van Dijkum
Els Nieveen van Dijkum
Pancreatic resections for pancreatic neuroendocrine tumors (pNET) may experience a higher complication rate than for pancreatic ductal adenocarcinoma (PDAC). This study aimed to determine the rate of the novel composite "Ideal Outcome" measure after resection for pNET, using PDAC as reference. This observational cohort study included all consecutive patients after pancreatic resection for pNET and PDAC using the nationwide Dutch Pancreatic Cancer Audit (2014-2021). The primary outcome was Ideal Outcome; absence of postoperative mortality, postoperative pancreatic fistulas (POPF) grade B/C, other major complications, prolonged length of stay, reoperations and readmissions. In total, 524 pNET and 2851 PDAC resections were included. The rate of Ideal Outcome was lower after resection for pNET (47.7% versus 55.7%; P<0.001) as compared to PDAC. This difference was driven by a lower rate of Ideal Outcome after pancreatoduodenectomy for pNET (37.7% versus 56.3%; P<0.001), with no difference after left pancreatectomy (54.5% versus 52.5%; P=0.598). Among the individual components of Ideal Outcome after pancreatoduodenectomy, the largest difference was a four times higher rate of POPF (32.1% versus 7.9%; P<0.001) after resection of pNET. Patients undergoing pancreatoduodenectomy for pNET have a reduced Ideal Outcome rate compared to patients with PDAC, related to a fourfold increased risk of POPF. This highlights the value of pNET-specific patient counseling and the need for effective POPF mitigation strategies.

1 February 2025 in British Journal of Surgery
Verified
Journal Article
Open access
LWLeonoor Wismans
Leonoor Wismans
THTessa E Hendriks
Tessa E Hendriks
JSJ Annelie Suurmeijer
J Annelie Suurmeijer
JNJoost J Nuyttens
Joost J Nuyttens
ABAnna Bruynzeel
Anna Bruynzeel
ACAnnalisa Comandatore
Annalisa Comandatore
Background: Postoperative pancreatic fistula is the main driver of morbidity and mortality after pancreatoduodenectomy. In high-risk patients, the rate of postoperative pancreatic fistula approaches 50%, whereas it is below 5% in patients with pancreatic cancer who receive neoadjuvant chemoradiotherapy. The aim of this study was to evaluate the safety, feasibility, and efficacy of preoperative stereotactic body radiotherapy on the pancreatic neck transection margin in high-risk patients undergoing pancreatoduodenectomy to prevent postoperative pancreatic fistula. Methods: In this prospective multicentre open-label single-arm trial (progressing from a safety run-in phase to a phase II design), patients undergoing pancreatoduodenectomy for neoplasms other than pancreatic ductal adenocarcinoma received a single preoperative stereotactic body radiotherapy dose of 12 Gy. Primary endpoints included safety (less than or equal to 15% grade 3–5 toxicity), feasibility (a significant change in pancreatic texture measured using a durometer), and efficacy (a 15% reduction in the grade B/C postoperative pancreatic fistula rate compared with patients from the Dutch Pancreatic Cancer Audit who were eligible but not included in this study). Secondary endpoints assessed tissue fibrosis (collagen density). Results: Overall, 38 patients were included, of whom 33 (87%) completed the study protocol and were included in the per-protocol analysis. The safety cut-off was met, with 3% grade 3–5 toxicity. Pancreatic tissue treated with stereotactic body radiotherapy showed increased firmness using a durometer (median of 47 (interquartile range 36–57) versus 37 (interquartile range 30–41) Shore OO units; P < 0.001) and a higher collagen density (median of 6.1% (interquartile range 4.4%–9.5%) versus 4.6% (interquartile range 2.5%–7.4%); P = 0.003). The grade B/C postoperative pancreatic fistula rate with stereotactic body radiotherapy was 57.6% (95% c.i. 41% to 74%), compared with 34% (95% c.i. 27% to 42%) in audit controls (P = 0.011). Conclusion: Preoperative stereotactic body radiotherapy is safe in high-risk patients undergoing pancreatoduodenectomy and increases parenchymal firmness and fibrosis, but fails to show evidence of efficacy.

10 January 2025 in Surgery for Obesity and Related Diseases
Verified
Journal Article
Closed access
ATAnnick Elianna Taselaar
Annick Elianna Taselaar
LWLeontine Henriëtte Wijngaarden
Leontine Henriëtte Wijngaarden
RKRené Alexander Klaassen
René Alexander Klaassen
EHErwin van der Harst
Erwin van der Harst
MDMartin Dunkelgrun
Martin Dunkelgrun
NLNicolle Litjens
Nicolle Litjens